Detalles de la búsqueda
1.
Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability.
J Biol Chem
; 300(1): 105555, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38072062
2.
Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound.
J Pharmacol Exp Ther
; 359(1): 37-44, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27440419
3.
AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies.
NPJ Parkinsons Dis
; 9(1): 91, 2023 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322068
4.
Sema3A Antibody BI-X Prevents Cell Permeability and Cytoskeletal Collapse in HRMECs and Increases Tip Cell Density in Mouse Oxygen-Induced Retinopathy.
Transl Vis Sci Technol
; 11(6): 17, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35727188
5.
Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic.
MAbs
; 14(1): 2104153, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35916739
6.
Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.
Oncoimmunology
; 11(1): 2080328, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35756842
7.
Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.
Bioorg Med Chem Lett
; 19(1): 62-6, 2009 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19041240
8.
Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.
Bioorg Med Chem Lett
; 18(12): 3641-5, 2008 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18501599
9.
Optimizing NBE PK/PD assays using the Gyrolab Affinity Software; conveniently within the bioanalyst's existing workflow.
Bioanalysis
; 10(6): 397-406, 2018 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29451404
10.
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.
MAbs
; 9(7): 1105-1117, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28786732
11.
Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design.
Bioorg Med Chem
; 14(23): 7953-61, 2006 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16919463
12.
Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction.
Anal Biochem
; 323(2): 224-33, 2003 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14656529
13.
Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction.
Org Biomol Chem
; 1(23): 4138-40, 2003 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-14685315
14.
Design and synthesis of indolo[2,3-a]quinolizin-7-one inhibitors of the ZipA-FtsZ interaction.
Bioorg Med Chem Lett
; 14(6): 1427-31, 2004 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-15006376
15.
Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction.
Bioorg Med Chem
; 12(19): 5115-31, 2004 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15351395
Resultados
1 -
15
de 15
1
Próxima >
>>